Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. E...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 15, 2024

Celebration Pediatrics Now Accepting Partner's Direct Health Insurance • The Chronicle of Higher Education Announces Winners of its 2024 Scholarships for Diversity in Media • Barbachano International Achieves Top 10 in Forbes' 2024 Ranking of America's Best Executive Recruiting Firms • HD Nursing Advocates for Women’s Health and Safety During National Women’s Health Week • Intersect Power Named in Sustainability Category of Fast Company’s 2024 World Changing Ideas Awards • Huddle Up Teams Up with the Bill of Rights Institute to Support Community Engagement and Mental Health • Digital Museums Canada awards over $2 million to 18 online projects • Groundbreaking Report Exposes Crisis in B2B Tech Thought Leadership: Only 44% Achieve Success • Building more child care spaces in New Brunswick • Central Texas YMCA Abuse Case Sparks Family Conversations: Vital Questions to Ask Kids • EarthTronics Introduces EarthBulb Direct Wire LED T8 Linear to Provide High Lumens and Maximum Energy Savings • Hondros College of Real Estate Earns Top Workplaces 2024 Award from Columbus CEO Magazine • CRN Honors IntelePeer’s Keli Davis on the 2024 Women of the Channel List • ECP Uses AI to Improve Medication Safety in Over 7,500 Senior Living Communities • Long-Term Care Market size is set to grow by USD 398.4 bn from 2023-2027, growing demand for long-term care from the aging popul • Lonch: Igniting the Entrepreneurial Spark while Reimagining Teamwork and Collaboration for the Virtual Workspace • Los Angeles Whistleblow: On the Heels of the NEW Recommendations of 3D Breast Cancer Screening (USPST) • Apple announces new accessibility features, including Eye Tracking, Music Haptics, and Vocal Shortcuts • Laconic Announces Peter Borish to Board of Directors • AMERICAN OIL COMPANY, OBSIDIAN ENERGY PETITIONS TO HAVE AN ENTIRE CANADIAN INDIGENOUS GOVERNMENT IMPRISONED FOR PEACEFULLY PRACT

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Q

WATERTOWN, Mass. , April 29 /Businesswire/ - Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information

The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website. To join by phone, participants can register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.